Liposome Stability via Lyophilization and Cryoprotectant Mediation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional liposomes are physically and chemically unstable, leading to aggregation, fusion, hydrolysis, and leakage of encapsulated drugs when stored in aqueous solutions, which compromises their stability and immune activity, and existing methods to improve stability, such as freeze-drying, often result in reduced efficacy and increased toxicity.
Innovation Solution
A composition comprising an immune modulator with a novel structure, specifically an analogue of lipopolysaccharide (LPS) with reduced toxicity, combined with a cationic liposome, which is prepared using a method involving lyophilization and rehydration to enhance stability and immunostimulatory activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If liposomes are stored in aqueous solution, then they are easy to manufacture and deliver drugs, but they undergo aggregation, fusion, hydrolysis, and leakage due to physical and chemical instability
Solution Approach 1:
The patent applies freeze-drying (lyophilization) to convert liposomes from liquid dispersion phase to solid powder phase for storage. This phase transition preserves liposome structure and prevents degradation reactions (hydrolysis, oxidation) that occur in aqueous solution, while maintaining the ability to rehydrate and restore functionality when needed
Solution Approach 2:
The patent introduces cryoprotectants as intermediary substances during the freeze-drying process. These cryoprotectants form protective matrices around liposomes during freezing and drying, preventing aggregation and fusion, and maintaining liposome integrity throughout the storage period
2Stability of the object's composition
If liposomes are converted to fine powder through freeze-drying, then stability is improved, but homogeneity deteriorates and physical and chemical properties change
Solution Approach 1:
Cryoprotectants serve as intermediary substances that maintain liposome homogeneity during freeze-drying. They form uniform protective matrices that prevent liposome aggregation and fusion, ensuring consistent size distribution and composition in the powdered form
Solution Approach 2:
The patent optimizes freeze-drying parameters including freezing rate, drying temperature, and pressure conditions to maintain liposome homogeneity. By carefully controlling these parameters, the liposomes retain their physical and chemical properties while achieving stable powdered form
3Reliability
If LPS is used for immune stimulation, then immune activation is enhanced, but toxicity increases causing sepsis
Solution Approach 1:
The patent extracts and isolates the immunostimulatory lipid A component from the toxic LPS structure. By removing the toxic polysaccharide chains while retaining the immunogenic lipid A core, the composition achieves immune activation without septic toxicity
Solution Approach 2:
The patent modifies specific regions of the LPS structure by selectively removing or modifying the polysaccharide chains while preserving the lipid A domain. This local modification approach maintains the immunostimulatory function while eliminating the toxic effects associated with the polysaccharide portion
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively enhances immune responses with improved stability and reduced toxicity, maintaining immunostimulatory activity and immune cell proliferation while mitigating cytotoxicity, making it suitable for vaccine formulations.
Implementation Method 1
Conventional liposomes have disadvantages of causing aggregation, fusion, hydrolysis of phospholipids, oxidation, leakage of encapsulated drugs
Implementation Method 2
a freeze-drying process is used in order to convert the liposomes into a fine powder
Implementation Method 3
LPS activates antigen-presenting cells through the secretion of cytokines by innate immune cells, the expression of costimulatory molecules on antigen-presenting cells
Data Source
AI summary
The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.